Pateclizumab

Pateclizumab (MLTA3698A) is a humanized antibody against lymphotoxin α (LTα), a transiently expressed cytokine on activated B and T cells (Th1, Th17), which are implicated in rheumatoid arthritis (RA) pathogenesis[1].

Product Specifications

CAS Number

[1202526-59-7]

Product Name Alternative

MLTA3698A; RG7415; PRO283698

UNSPSC

12352203

Target

Others

Type

Inhibitory Antibodies

Related Pathways

Others

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/pateclizumab.html

Purity

99.0

Solubility

10 mM in DMSO

Smiles

[Pateclizumab]

Molecular Weight

(144.9 kDa)

References & Citations

[1]Brinda Emu, et al. Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial.